comparemela.com

Latest Breaking News On - Sihuan pharm - Page 1 : comparemela.com

Oxcarbazepine Market Size And Growth Rate 2023-2030 | By Geographical Regional Analysis

Oxcarbazepine Market Size And Growth Rate 2023-2030 | By Geographical Regional Analysis
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA

Sihuan Pharmaceutical(0460 HK): Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing

China Medical System (0867 HK) Acquires a Dermatology Specialty Company: A Tough Player the Race

China Medical System (0867.HK) Acquires a Dermatology Specialty Company: A Tough Player the Race By GeLongHui HONG KONG, Feb 5, 2021 - (ACN Newswire) - On February 1, China Medical System (0867.HK) announced that its subsidiary had acquired Luqa Ventures Co., Limited ( Luqa ), a dermatology specialty company. This acquisition expanded its product portfolio to include Luqa s dermatology products and marked the first foray into the medical aesthetic industry for China Medical System. Why medical aesthetics? What is the significance of this acquisition? 1. Consolidating the Skin Management Business and Entering the Medical Aesthetic Market: Acquiring Luqa to Explore a New Growth Engine According to its official website, established in 2010, Luqa is an innovative enterprise with skin treatment and medical aesthetic solutions as its core business.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.